Author Correction: Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial (Nature Medicine, (2023), 29, 11, (2825-2834), 10.1038/s41591-023-02568-1)

Matthew D. Galsky, Siamak Daneshmand, Sudeh Izadmehr, Edgar Gonzalez-Kozlova, Kevin G. Chan, Sara Lewis, Bassam El Achkar, Tanya B. Dorff, Jeremy Paul Cetnar, Brock O. Neil, Anishka D’Souza, Ronac Mamtani, Christos Kyriakopoulos, Tomi Jun, Mahalya Gogerly-Moragoda, Rachel Brody, Hui Xie, Kai Nie, Geoffrey Kelly, Amir HorowitzYayoi Kinoshita, Ethan Ellis, Yohei Nose, Giorgio Ioannou, Rafael Cabal, Diane M. Del Valle, G. Kenneth Haines, Li Wang, Kent W. Mouw, Robert M. Samstein, Reza Mehrazin, Nina Bhardwaj, Menggang Yu, Qianqian Zhao, Seunghee Kim-Schulze, Robert Sebra, Jun Zhu, Sacha Gnjatic, John Sfakianos, Sumanta K. Pal

Research output: Contribution to journalComment/debate

Abstract

Correction to: Nature Medicine, published online 2 October 2023. In the version of the article initially published, Diane M. Del Valle (Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA) was missing from the author list; the surname of Amir Horowitz appeared incorrectly (Horwitz); the ClinicalTrials.gov identifier in the Abstract (now listing) was incorrect; and the Acknowledgements were missing additional thanks. The updates now appear in the HTML and PDF versions of the article.

Original languageEnglish
JournalNature Medicine
DOIs
StateAccepted/In press - 2024

Fingerprint

Dive into the research topics of 'Author Correction: Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial (Nature Medicine, (2023), 29, 11, (2825-2834), 10.1038/s41591-023-02568-1)'. Together they form a unique fingerprint.

Cite this